Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
TG THERAPEUTICS, INC. reported the three months ended December 31, 2022 results: revenue approximately zero, net income $53.0 million.
- Period
- the three months ended December 31, 2022
- Revenue
- approximately zero
- Net income
- $53.0 million
- Result
- reported results
Exact text from the filing
Product Revenue, net: Product revenue, net was approximately zero and $2.6 million for the three and twelve months ended December 31, 2022. Net product revenues during the year represent U.S. sales of UKONIQ, which received approval in February of 2021 and was withdrawn from the U.S. market effective May 31, 2022. · R&D Expenses: Total research and development (R&D) expense was $29.6 million and $125.4 million for the three and twelve months ended December 31, 2022, compared to $62.6 million and $222.6 million for the three and twelve months ended December 31, 2021. The decrease in R&D expense is primarily attributable to reduced clinical trial related expenses, license milestones and manufacturing expense, decreased headcount and lower fees paid to consultants and outside service providers, as well as a decrease in non-cash compensation R&D expense during the twelve months ended December 31, 2022 over the comparable period in 2021. · SG&A Expenses: Total selling, general and administr
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
TG THERAPEUTICS, INC. reported the twelve months ended December 31, 2022 results: revenue $2.6 million, net income $198.3 million.
- Period
- the twelve months ended December 31, 2022
- Revenue
- $2.6 million
- Net income
- $198.3 million
- Result
- reported results
Exact text from the filing
Product Revenue, net: Product revenue, net was approximately zero and $2.6 million for the three and twelve months ended December 31, 2022. Net product revenues during the year represent U.S. sales of UKONIQ, which received approval in February of 2021 and was withdrawn from the U.S. market effective May 31, 2022. · R&D Expenses: Total research and development (R&D) expense was $29.6 million and $125.4 million for the three and twelve months ended December 31, 2022, compared to $62.6 million and $222.6 million for the three and twelve months ended December 31, 2021. The decrease in R&D expense is primarily attributable to reduced clinical trial related expenses, license milestones and manufacturing expense, decreased headcount and lower fees paid to consultants and outside service providers, as well as a decrease in non-cash compensation R&D expense during the twelve months ended December 31, 2022 over the comparable period in 2021. · SG&A Expenses: Total selling, general and administr
View on SEC.gov